Skip to Content
Merck
CN

30553

Samarium(III) ionophore I

Selectophore

Synonym(s):

Glipizide, 1-Cyclohexyl-3-{4-[2-(5-methylpyrazine-2-carboxamido)ethyl]phenylsulfonyl}urea

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):
C21H27N5O4S
CAS Number:
Molecular Weight:
445.54
UNSPSC Code:
26111700
PubChem Substance ID:
EC Number:
249-427-6
MDL number:
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist


product line

Selectophore

SMILES string

Cc1cnc(cn1)C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)NC3CCCCC3

InChI

1S/C21H27N5O4S/c1-15-13-24-19(14-23-15)20(27)22-12-11-16-7-9-18(10-8-16)31(29,30)26-21(28)25-17-5-3-2-4-6-17/h7-10,13-14,17H,2-6,11-12H2,1H3,(H,22,27)(H2,25,26,28)

InChI key

ZJJXGWJIGJFDTL-UHFFFAOYSA-N

General description

Visit our Sensor Applications portal to learn more.

Other Notes

Indicator electrode for the potentiometric determination of Sm(III) with EDTA

Legal Information

Selectophore is a trademark of Merck KGaA, Darmstadt, Germany


Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

Regulatory Information

新产品

This item has



Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library



K M Pantalone et al.
Diabetes, obesity & metabolism, 14(9), 803-809 (2012-04-11)
It remains uncertain if differences in mortality risk exist among the sulfonylureas, especially in patients with documented coronary artery disease (CAD). The purpose of this study was to assess the overall mortality risk of the individual sulfonylureas versus metformin in
Wilma Erhardt et al.
Clinical drug investigation, 32(3), 189-202 (2012-02-02)
The lack of adequate glycaemic control for patients with type 2 diabetes mellitus (T2DM), especially with existing second-line therapies, represents an unmet medical need. Of the newer therapies, the incretin-based medicines, such as saxagliptin, look promising to consolidate second-line pharmacotherapy.
M.R. Ganjali et al.
Sensors and Actuators B, Chemical, 89, 21-21 (2003)